Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Disruption of NEAT1-transcriptional network identifies targetable non-genetic dependencies in multiple myeloma

Noemi Puccio, Christian Boni, Federica Torricelli, Emanuele Vitale, Elisa Taiana, Domenica Ronchetti, Valentina Fragliasso, Selene Mallia, Giulia Gambarelli, Roberto Piva, Niccolo Bolli, Stefano Luminari, Alessia Ciarrocchi, Antonino Neri

Blood (2025) 146 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2025-3945

Published: 2025

Journal Articles

Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis

Bruno Fattizzo, Francesca Lazzaroni, Filippo Viviani, Emanuele Calvi, Giacinto Luca Pedone, Marta Bortolotti, Akihiro Maeda, Marta Lionetti, Alessio Marella, Antonio Matera, Niccolo Bolli, Francesco Passamonti, Wilma Barcellini, Matteo Claudio Da Vià

Blood (2025) 146 (Supplement 1): 1122.

https://doi.org/10.1182/blood-2025-1122

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Blood (2025) 146 (12): 1476–1492.

https://doi.org/10.1182/blood.2024024719

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes

Blood (2025) 146 (5): 571–584.

https://doi.org/10.1182/blood.2024026236

Published: 2025

Includes: Supplemental data

Journal Articles

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

Blood (2025) 145 (26): 3124–3138.

https://doi.org/10.1182/blood.2024025643

Published: 2025

Includes: Supplemental data

Journal Articles

For how long has this problem been there?

Niccolò Bolli, Matteo Claudio da Vià

Blood (2025) 145 (5): 462–463.

https://doi.org/10.1182/blood.2024027361

Published: 2025

Journal Articles

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Daniele Cattaneo, Barbara Mora, Cristina Bucelli, Margherita Maffioli, Elena Maria Elli, Giulia Benevolo, Valentina Bellani, Emilia Scalzulli, Filippo Branzanti, Paola Bianchi, Marta Lionetti, Bruno Martino, Umberto Gianelli, Niccolò Bolli, Francesca Palandri, Massimo Breccia, Dario Consonni, Alessandra Iurlo

Blood (2024) 144 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2024-211145

Published: 2024

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Claudio Da Vià, Mansour Poorebrahim, Sacha Benaoudia, David Jung, Elham Hasheminasabgorji, Niccolò Bolli, Nizar J. Bahlis, Paola Neri

Blood (2024) 144 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2024-208842

Published: 2024

Journal Articles

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Vià, Alessio Marella, Antonio Matera, Akihiro Maeda, Nicolo Rampi, Claudia Leoni, Federico Mazzon, Elena Tagliaferri, Mariarita Sciumè, Marta Lionetti, Bruno Fattizzo, Francesco Passamonti, Nicola Stefano Fracchiolla, Niccolò Bolli

Blood (2024) 144 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2024-208253

Published: 2024

Journal Articles

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Paolo Lopedote, Alfredo Marchetti, Benjamin Evans, Tianzeng Chen, Maria Moscvin, Niccolò Bolli, Giada Bianchi

Blood (2023) 142 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2023-190905

Published: 2023

Journal Articles

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Benjamin Diamond, Niccolò Bolli, Paolo Corradini, David Coffey, Ola Landgren, Benedetto Bruno, Mario Boccadoro, Massimo Massaia, Francesco Maura, Alessandra Larocca

Blood (2023) 142 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2023-182301

Published: 2023

Journal Articles

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Noemi Puccio, Elisa Taiana, Gloria Manzotti, Elisabetta Mereu, Domenica Ronchetti, Cecilia Bandini, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Veronica Manicardi, Valentina Fragliasso, Nicola Amodio, Niccolò Bolli, Stefano Luminari, Alessia Ciarrocchi, Roberto Piva, Antonino Neri

Blood (2023) 142 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2023-190131

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Blood (2022) 140 (Supplement 1): 2088–2090.

https://doi.org/10.1182/blood-2022-158992

Published: 2022

Journal Articles

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Fabio Serpenti, Anushka Shankar, Nicolo' Rampi, Cristina Mocellin, Cecilia Fidanza, Maria Cecilia Goldaniga, Giorgia Saporiti, Matteo Claudio Da Via, Giulia Galassi, Loredana Pettine, Filippo Bagnoli, Niccolo Bolli, Luca Baldini, Alessandra Pompa, Francesco Onida

Blood (2022) 140 (Supplement 1): 12576–12577.

https://doi.org/10.1182/blood-2022-169454

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Disruption of NEAT1-transcriptional network identifies targetable non-genetic dependencies in multiple myeloma

Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment

Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

For how long has this problem been there?

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Prevalence, Characteristics, and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in AL Amyloidosis

Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

Novel Combinatorial Therapeutic Options in NEAT1-Depleted Multiple Myeloma Cells By the Integration of in Vitro and in silico Drug Screening Approaches

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only